# Poolbeg Pharma sign agreement with Centre for Human Drug Research in the Netherlands

- Link: https://www.directorstalkinterviews.com/poolbeg-pharma-sign-agreement-with-centre-for-human-drug-research-in-the-netherlands/4121059183
- Published: 2022-03-31T07:18:27+01:00
- Author: Giles

Poolbeg Pharma ([LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l),
OTCQB: POLBF) has announced that it has signed a Clinical Trial Agreement with the
Centre for Human Drug Research (CHDR) in the Netherlands for the completion of a
bacterial lipopolysaccharide (‘LPS’) human challenge study of POLB 001, which is
due to commence in June 2022. First results are expected before the end of 2022 
at which point the Company aims to rapidly monetise by partnering or out licensing
the asset to pharma / biotech for further development.

As part of this study, which is being completed in line with the Company’s capital
light approach, researchers will stimulate the immune systems of healthy volunteers
with LPS in a safe and controlled clinical environment. LPS emulates a robust immune
response acting as a simulant for the hyperinflammatory effects associated with 
severe influenza infections which CHDR will use to measure the efficacy of POLB 
001 as its mode of action is to block this hyper-immune response. This differs from
existing treatments because it targets the host immune response rather than the 
virus itself and is therefore unaffected by viral variance. Poolbeg has defined 
and formulated the oral administration of POLB 001 and already has sufficient grade
and quantities of the drug to utilise immediately in the forthcoming human challenge
study.

In the study the LPS will be administered both intradermally (a shallow injection)
and intravenously (an injection of a vein). By administering the LPS intradermally,
the Company can gather data around the localised response of the body to POLB 001.
By then administering the LPS intravenously, data can be gathered around the full
body systemic response to POLB 001. By using both methods within one study, the 
Company will efficiently and cost effectively collect both local and systemic efficacy
data, increasing the value of the data package which will be attractive to potential
partners. Overall, the study will generate key human data on the efficacy of POLB
001 in dampening the immune response in otherwise healthy volunteers.

> **Jeremy Skillington, PhD, CEO of Poolbeg Pharma said:**
> “We are moving forward at a strong pace to enable the upcoming human challenge
> clinical trial of POLB 001 to commence as planned. This study will provide invaluable
> early human data on the efficacy of this asset in dampening the immune response
> after being stimulated, thereby limiting the damage it can otherwise cause in 
> a setting such as severe influenza.
> We will continue to provide updates as we progress towards commencing the study
> in June 2022 with results due before the end of the year. We are looking forward
> to receiving the broad spectrum of data from this study, given that it will be
> completed both intradermally and intravenously, thus maximizing the data package
> that can be shared with any potential pharma or biotech licensing partner.”

**More Information on influenza and POLB 001**

The threat of influenza is significant, with cases at their highest globally since
the COVID-19 pandemic. Influenza affects 1 in 8 of the global population and causes
500,000 deaths each year. In cases of severe influenza, the body produces an over-
heightened immune response that can cause more damage to the body than the virus
itself.

POLB 001 was identified using the unique disease progression data available from
human challenge trials. Data from human challenge studies are unique in that they
track a healthy subject through disease to recovery in carefully controlled and 
monitored isolation units, collecting samples throughout the course of disease, 
and vitally collecting matched baseline and follow-up samples before and after infection.
By mapping the entire biological process of disease, it provides a platform to help
identify promising disease relevant pathways in the pursuit of novel drug targets.
The Company is now progressing two artificial intelligence programmes to complete
analysis of influenza and Respiratory Syncytial Virus (RSV) data faster and more
cost effectively than previously possible.

*Good Manufacturing Practice (GMP) is the regulatory code of standards that a medicine’s
manufacturer must meet in its production processes to enable administration to humans.

Share on:
